New Details Emerge in Johnson & Johnson's Pursuit of Actelion

New Details Emerge in Johnson & Johnson's Pursuit of Actelion


Back in November, it was confirmed that healthcare conglomerate Johnson & Johnson and Actelion were in discussions, with J&J on the hunt for a new acquisition. Johnson & Johnson reportedly offered Actelion, which has long strived to remain independent, $26 billion in order to gain hold of its leading portfolio of pulmonary arterial hypertension drugs.



from Biotech News